Numis Securities Ltd reissued their buy rating on shares of Clinigen Group PLC (LON:CLIN) in a research report released on Wednesday morning. Numis Securities Ltd currently has a GBX 933 ($12.18) price target on the stock.
A number of other brokerages have also recently issued reports on CLIN. N+1 Singer reissued a buy rating and set a GBX 800 ($10.44) price objective on shares of Clinigen Group PLC in a report on Wednesday, September 28th. Stifel Nicolaus reissued a buy rating and set a GBX 800 ($10.44) price objective on shares of Clinigen Group PLC in a report on Wednesday, July 20th. Finally, Peel Hunt reissued a buy rating and set a GBX 1,000 ($13.05) price objective on shares of Clinigen Group PLC in a report on Wednesday, September 28th. Five equities research analysts have rated the stock with a buy rating, Clinigen Group PLC has a consensus rating of Buy and a consensus price target of GBX 856.60 ($11.18).
Clinigen Group PLC (LON:CLIN) opened at 732.60999 on Wednesday. Clinigen Group PLC has a 52-week low of GBX 492.75 and a 52-week high of GBX 739.50. The stock’s 50 day moving average is GBX 655.62 and its 200 day moving average is GBX 599.30. The company’s market cap is GBX 839.56 million.
The firm also recently declared a dividend, which will be paid on Friday, November 25th. Investors of record on Thursday, November 3rd will be issued a GBX 2.70 ($0.04) dividend. This represents a dividend yield of 0.38%. This is a boost from Clinigen Group PLC’s previous dividend of $1.30. The ex-dividend date of this dividend is Thursday, November 3rd.
Clinigen Group PLC Company Profile
Clinigen Group plc is a United Kingdom-based global pharmaceutical and services company. The Company consists of four businesses that provide medicines to patients with unmet needs, through clinical trials, licensed and unlicensed supply. It operates through four segments: Clinigen Clinical Trial Services (CTS), Idis Managed Access (MA), Idis Global Access (GA) and Clinigen Specialty Pharmaceuticals (SP).
Receive News & Ratings for Clinigen Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.